Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Cancers (Basel). 2014 Jun 27;6(3):1298-327. doi: 10.3390/cancers6031298.
Matrix metalloproteinases (MMPs), a group of zinc-dependent endopeptidases involved in the degradation of the extracellular matrix, play an important role in tissue remodeling associated with various physiological processes such as morphogenesis, angiogenesis, and tissue repair, as well as pathological processes including cirrhosis, arthritis and cancer. The MMPs are well established as mediators of tumor invasion and metastasis by breaking down connective tissue barriers. Although there has been a vast amount of literature on the role of MMPs in invasion, metastasis and angiogenesis of various cancers, the role of these endopeptidases in prostate cancer progression has not been systematically reviewed. This overview summarizes findings on the tissue and blood expression of MMPs, their function, regulation and prognostic implication in human prostate cancer, with a focus on MMP-2, -7, -9, MT1-MMP and tissue inhibitor of metalloproteinase 1 (TIMP-1). This review also summarizes the efficacy and failure of early-generation matrix metalloproteinase inhibitors (MMPIs) in the treatment of metastatic prostate cancer and highlights the lessons and challenges for next generation MMPIs.
基质金属蛋白酶(MMPs)是一组锌依赖性内肽酶,参与细胞外基质的降解,在与各种生理过程相关的组织重塑中发挥重要作用,如形态发生、血管生成和组织修复,以及包括肝硬化、关节炎和癌症在内的病理过程。MMPs 通过分解结缔组织屏障,被证实是肿瘤侵袭和转移的介质。尽管有大量文献研究 MMPs 在各种癌症的侵袭、转移和血管生成中的作用,但这些内肽酶在前列腺癌进展中的作用尚未得到系统综述。这篇综述总结了 MMPs 在人前列腺癌中的组织和血液表达、功能、调节以及预后意义的研究结果,重点介绍了 MMP-2、-7、-9、MT1-MMP 和金属蛋白酶组织抑制剂 1(TIMP-1)。本文还总结了早期一代基质金属蛋白酶抑制剂(MMPI)在转移性前列腺癌治疗中的疗效和失败,并强调了下一代 MMPIs 的经验和挑战。